These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28432455)

  • 1. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
    Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
    Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
    Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
    Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
    Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases.
    Mitchell D; Olive C
    Mol Immunol; 2010 Jul; 47(11-12):2065-73. PubMed ID: 20451253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide.
    Chen L; Arora M; Yarlagadda M; Oriss TB; Krishnamoorthy N; Ray A; Ray P
    J Immunol; 2006 Aug; 177(4):2373-83. PubMed ID: 16887999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
    van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
    J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.
    Berghöfer B; Haley G; Frommer T; Bein G; Hackstein H
    J Immunol; 2007 Apr; 178(7):4072-9. PubMed ID: 17371961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.
    Haas F; Yamauchi K; Murat M; Bernasconi M; Yamanaka N; Speck RF; Nadal D
    J Virol; 2014 Sep; 88(17):10002-12. PubMed ID: 24942583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
    Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
    Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
    Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
    Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells.
    Sriram U; Xu J; Chain RW; Varghese L; Chakhtoura M; Bennett HL; Zoltick PW; Gallucci S
    PLoS One; 2014; 9(1):e87668. PubMed ID: 24489947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.